Silvia Hernández‐Llodrà

<i><scp>CD</scp>274</i> (<i><scp>PDL</scp>1</i>) and <i><scp>JAK</scp>2</i> genomic amplifications in pulmonary squamous‐cell and adenocarcinoma patients

Sergi Clavé, Lara Pijuán, David Casadevall et al. · Histopathology · 2017 · 33 citations · Full text

Immunohistochemical expression of mismatch repair proteins (MSH2, MSH6, MLH1, and PMS2) in prostate cancer: correlation with grade groups (WHO 2016) and ERG and PTEN status

Raquel Albero‐González, Silvia Hernández‐Llodrà, Núria Juanpere et al. · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · 2019 · 26 citations

Urology, Medicine, Pathology +6

ERG overexpression plus SLC45A3 (prostein) and PTEN expression loss: Strong association of the triple hit phenotype with an aggressive pathway of prostate cancer progression

Silvia Hernández‐Llodrà, Núria Juanpere, Silvia de Muga et al. · Oncotarget · 2017 · 23 citations · Full text

FOXO1 down-regulation is associated with worse outcome in bladder cancer and adds significant prognostic information to p53 overexpression

Josep Lloreta, Alba Font‐Tello, Núria Juanpere et al. · Human Pathology · 2017 · 20 citations

Urology, Worse Outcome, Genitourinary Cancer +9

<i>SPOP</i> and <i>FOXA1</i> mutations are associated with PSA recurrence in <i>ERG</i> wt tumors, and <i>SPOP</i> downregulation with <i>ERG</i>‐rearranged prostate cancer

Silvia Hernández‐Llodrà, Laura Segalés, Ainara Safont et al. · The Prostate · 2019 · 20 citations